Cytosorbents Crp (CTSO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cytosorbents Crp (CTSO) has a cash flow conversion efficiency ratio of 2.324x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.75 Million) by net assets ($-751.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Cytosorbents Crp market cap and net worth for the company's overall valuation and market capitalisation.
Cytosorbents Crp - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Cytosorbents Crp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cytosorbents Crp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cytosorbents Crp ranked by their cash flow conversion efficiency. Explore earnings quality score of Cytosorbents Crp to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lleidanetworks Serveis Telematics SA
MC:LLN
|
0.270x |
|
Hunesion Co.Ltd
KQ:290270
|
-0.024x |
|
SAMJIN Co. Ltd
KQ:032750
|
0.041x |
|
Pelikan International Corp
KLSE:5231
|
-0.039x |
|
Blue Shark Power System SA
PA:MLBSP
|
N/A |
|
Arzum Elektrikli Ev Aletleri Sanayi ve Ticaret AS
IS:ARZUM
|
7.089x |
|
Redflow Ltd
AU:RFX
|
-0.849x |
|
Otto Holding AS
IS:OTTO
|
0.053x |
Annual Cash Flow Conversion Efficiency for Cytosorbents Crp (2004–2025)
The table below shows the annual cash flow conversion efficiency of Cytosorbents Crp from 2004 to 2025. View CTSO live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.90 Million | $-12.38 Million | -2.097x | -61.41% |
| 2024-12-31 | $11.11 Million | $-14.43 Million | -1.299x | -39.62% |
| 2023-12-31 | $23.28 Million | $-21.66 Million | -0.930x | -16.57% |
| 2022-12-31 | $35.37 Million | $-28.23 Million | -0.798x | -256.62% |
| 2021-12-31 | $62.58 Million | $-14.01 Million | -0.224x | -215.84% |
| 2020-12-31 | $79.22 Million | $-5.61 Million | -0.071x | +98.55% |
| 2019-12-31 | $3.42 Million | $-16.76 Million | -4.903x | -666.00% |
| 2018-12-31 | $16.93 Million | $-10.84 Million | -0.640x | -1.68% |
| 2017-12-31 | $10.26 Million | $-6.46 Million | -0.630x | -104.43% |
| 2016-12-31 | $-474.09K | $-6.73 Million | 14.198x | +1393.96% |
| 2015-12-31 | $8.21 Million | $-9.01 Million | -1.097x | +34.72% |
| 2014-12-31 | $3.96 Million | $-6.66 Million | -1.681x | -787.19% |
| 2013-12-31 | $-14.27 Million | $-3.49 Million | 0.245x | -21.37% |
| 2012-12-31 | $-11.63 Million | $-3.62 Million | 0.311x | +102.59% |
| 2011-12-31 | $318.34K | $-3.83 Million | -12.026x | -335.25% |
| 2010-12-31 | $-484.58K | $-2.48 Million | 5.112x | +342.31% |
| 2009-12-31 | $1.27 Million | $-2.67 Million | -2.110x | -110.46% |
| 2008-12-31 | $2.36 Million | $-2.37 Million | -1.002x | -103.98% |
| 2007-12-31 | $-104.30K | $-2.63 Million | 25.196x | +2189.66% |
| 2006-12-31 | $2.36 Million | $-2.85 Million | -1.206x | -299.98% |
| 2005-12-31 | $-82.93K | $-50.00K | 0.603x | -27.65% |
| 2004-12-31 | $-60.00K | $-50.00K | 0.833x | -- |
About Cytosorbents Crp
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and criti… Read more